The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

Prostate cancer is the second most common malignancy in men and androgen deprivation
therapy is the first‐line therapy. However, most cases will eventually develop castration …

Background Tumour acidosis is considered to play a central role in promoting cancer
invasion and migration, but few studies have investigated in vivo how tumour pH correlates …

Intratumoral heterogeneity can occur via phenotype transitions, often after chronic exposure
to targeted anticancer agents. This process, termed lineage plasticity, is associated with …

Hypoxia is a ubiquitous feature of solid tumors, which plays a key role in tumor angiogenesis
and resistance development. Conventional hypoxia detection methods lack continuous …

Cancer stem cells are a subset of cells within the tumor that possess the ability to self-renew
as well as differentiate into different cancer cell lineages. The exact mechanisms by which …

The growth of solid tumors is inevitably accompanied by hypoxia and angiogenesis.
Understanding the true state of tissue hypoxia and angiogenesis during tumor progression …

Androgen deprivation therapy suppresses tumor androgen receptor (AR) signaling by
depleting circulating testosterone and is a mainstay treatment for advanced prostate cancer …

Effective treatments for patients with metastatic castration-resistant prostate cancer following
disease progression on enzalutamide are currently an unmet clinical need. Simultaneous …

Hypoxia is frequently observed in human prostate cancer, and is associated with
chemoresistance, radioresistance, metastasis, and castrate-resistance. Our purpose in these …